INLX vs DOCU vs OTLK

For growth investors, DocuSign, Inc.

(DOCU) is the stronger pick with 8. 2% revenue growth year-over-year, versus 6. 7% for Intellinetics, Inc. (INLX). DocuSign, Inc. (DOCU) offers the better valuation at 32. 6x trailing P/E (12. 7x forward), making it the more compelling value choice. Analysts rate DocuSign, Inc. (DOCU) a "Hold" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Intellinetics, Inc.

(INLX) delivered a total return of +77. 5%, compared to -99. 5% for Outlook Therapeutics, Inc. (OTLK). Over 10 years, the gap is even starker: DOCU returned +20. 6% versus OTLK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Intellinetics, Inc.

(INLX) is the lower-risk stock at -0. 44β versus Outlook Therapeutics, Inc. 's 1. 47β — meaning OTLK is approximately -432% more volatile than INLX relative to the S&P 500. On balance sheet safety, DocuSign, Inc. (DOCU) carries a lower debt/equity ratio of 10% versus 33% for Intellinetics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), DocuSign, Inc.

(DOCU) is pulling ahead at 8. 2% versus 6. 7% for Intellinetics, Inc. (INLX). On earnings-per-share growth, the picture is similar: Outlook Therapeutics, Inc. grew EPS 55. 9% year-over-year, compared to -218. 2% for Intellinetics, Inc.. Over a 3-year CAGR, INLX leads at 16. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DocuSign, Inc.

(DOCU) is the more profitable company, earning 9. 6% net margin versus -44. 2% for Outlook Therapeutics, Inc. — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCU leads at 9. 3% versus -47. 4% for OTLK. At the gross margin level — before operating expenses — DOCU leads at 79. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Intellinetics, Inc.

(INLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 44)). Both have compounded well over 10 years (INLX: -99. 8%, OTLK: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (INLX (Technology) and DOCU (Technology) and OTLK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.